Key Financial Inc Trims Stock Position in Pfizer Inc. (NYSE:PFE)

Key Financial Inc cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 73,092 shares of the biopharmaceutical company’s stock after selling 3,512 shares during the quarter. Key Financial Inc’s holdings in Pfizer were worth $2,104,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Adage Capital Partners GP L.L.C. increased its position in shares of Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the period. LifePlan Financial LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $255,000. Brookstone Capital Management boosted its stake in shares of Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares in the last quarter. ETF Store Inc. boosted its stake in shares of Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares in the last quarter. Finally, Farmers Trust Co. boosted its stake in shares of Pfizer by 2.0% during the fourth quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after purchasing an additional 4,410 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.27 during trading on Wednesday, hitting $25.42. 43,604,913 shares of the company’s stock were exchanged, compared to its average volume of 42,571,164. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The business has a 50-day simple moving average of $27.23 and a 200-day simple moving average of $28.79. Pfizer Inc. has a 52-week low of $25.26 and a 52-week high of $41.33. The stock has a market capitalization of $143.94 billion, a price-to-earnings ratio of 71.36, a PEG ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 earnings per share. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, research analysts forecast that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PFE. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.